UHC Updates Rituximab Policy to Require Use of Biosimilars

As of Oct. 1, UnitedHealthcare (UHC) requires that patients fail to respond to both FDA-approved rituximab biosimilars prior to receiving approval for rituximab. Exception: Rituximab-pvvr (Ruxience) is not FDA approved for rheumatoid arthritis.
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Billing/Coding biosimilar substitution non-medical switching prior authorization rituximab rituximab-abbs UnitedHealthCare (UHC) Source Type: research